M.D. Anderson Cancer Center

p27(KIP1) has a novel role in down-regulation of telomerase activity

Published in Lab Business Week, January 12th, 2004

p27(KIP1) has a novel role in down-regulation of telomerase activity, researchers report.

According to a study from the United States, "The cyclin-dependent kinase inhibitor p27(KIP1) is considered not only a prognostic factor in cancer, but also a promising anticancer agent.

"However, the relationship between p27 KIP I and telomerase, that has potential as tumor marker, remains to be elucidated. In this study, using the recombinant adenoviral vector expressing p27(KIP1) (Adp27(KIP1)), we investigated whether p27(KIP1) affects telomerase activity in malignant glioma U373-MG cells," wrote T. Kanzawa and colleagues, University of Texas, M.D. Anderson...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2004-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry